News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients Michael O'Riordan August 30, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Opinion Editor's Corner ESC 2023 What’s Going to Be Hot at ESC 2023? Shelley Wood August 15, 2023
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Conference News ESC 2020 Revascularization Benefits ISCHEMIA Patients With Mild LV Dysfunction or HF Michael O'Riordan August 31, 2020
News Conference News ESC 2020 Trimetazidine Safe but Not Protective Long-term After PCI Caitlin E. Cox August 30, 2020
News Conference News ESC 2019 Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis Yael L. Maxwell September 12, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019